-
1.发明授权公开(公告)号：US12043610B2
公开(公告)日：2024-07-23
申请号：US17730463
申请日：2022-04-27
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Weihe Zhang , Peng-Cheng Lu , Minwan Wu , Wei Lv , Trung Xuan Nguyen , Zhao Dang , Venkat R. Chintareddy , V. Satish Kumar , Krishnan Raman
IPC分类号： C07D401/10 , C07D209/12 , C07D261/20 , C07D307/80 , C07D333/64 , C07D401/12 , C07D405/10
CPC分类号： C07D401/10 , C07D209/12 , C07D261/20 , C07D307/80 , C07D333/64 , C07D401/12 , C07D405/10
摘要： Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
-
公开(公告)号：US20240239752A1
公开(公告)日：2024-07-18
申请号：US18286615
申请日：2022-04-14
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Weihe Zhang , Peng-Cheng Lu , Zhao Dang , Krishnan Raman
IPC分类号： C07D231/56 , A61K31/343 , A61K31/352 , A61K31/416 , A61K31/4178 , A61K31/4184 , A61K31/4196 , A61K31/423 , A61K31/427 , A61K31/437 , A61K31/4375 , A61K31/443 , A61K31/4439 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/5025 , A61K31/517 , A61K31/519 , C07D217/22 , C07D307/81 , C07D311/96 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D405/10 , C07D405/12 , C07D405/14 , C07D413/04 , C07D417/12 , C07D471/04 , C07D487/04
CPC分类号： C07D231/56 , A61K31/343 , A61K31/352 , A61K31/416 , A61K31/4178 , A61K31/4184 , A61K31/4196 , A61K31/423 , A61K31/427 , A61K31/437 , A61K31/4375 , A61K31/443 , A61K31/4439 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/5025 , A61K31/517 , A61K31/519 , C07D217/22 , C07D307/81 , C07D311/96 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D405/10 , C07D405/12 , C07D405/14 , C07D413/04 , C07D417/12 , C07D471/04 , C07D487/04
摘要： Disclosed are compounds of formulae (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity, such as Netherton Syndrome.
-
公开(公告)号：US20230303611A1
公开(公告)日：2023-09-28
申请号：US18100192
申请日：2023-01-23
发明人： Pravin L. Kotian , Zhao Dang , Minwan Wu
摘要： Provided are methods of making the active 5′-triphosphate form of galidesivir (compound 1) and the active 5′-triphosphate form of azasugar nucleoside analogues (compound 2):
a potent anti-viral compound useful for broad spectrum treatment, suppression, and prevention of viral infections. The syntheses of compound 1 and compound 2 can be achieved via selective formation of protected intermediate 1b and protected intermediate 2b, respectively:-
公开(公告)号：US11708332B2
公开(公告)日：2023-07-25
申请号：US17526377
申请日：2021-11-15
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Minwan Wu , Venkat R. Chintareddy , V. Satish Kumar , Weihe Zhang
IPC分类号： C07D231/14 , C07D403/12 , C07D401/14 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/12
CPC分类号： C07D231/14 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D413/04 , C07D413/12 , C07D417/12
摘要： Disclosed are compounds of formula I
as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.-
公开(公告)号：US20220332723A1
公开(公告)日：2022-10-20
申请号：US16622816
申请日：2018-06-14
发明人： Pravin L. Kotian , Yarlagadda S. Babu , V. Satish Kumar , Weihe Zhang , Peng-Cheng Lu , Krishnan Raman
IPC分类号： C07D491/048 , C07D487/04 , C07D495/04 , C07D403/12 , C07D403/14 , C07D471/04 , C07D513/04 , C07D401/14 , C07D405/14 , C07D405/12
摘要： Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
-
公开(公告)号：US20220160694A1
公开(公告)日：2022-05-26
申请号：US17602674
申请日：2020-04-08
发明人： Yarlagadda Babu , Viral Kansara , Rick McElheny
IPC分类号： A61K31/4418 , A61K9/00 , C07K16/40 , A61P27/02
摘要： This disclosure is generally in the field of ophthalmic therapies, and more particularly to the treatment of various ocular diseases and conditions by non-surgical administration to the eye of a subject of a drug composition described herein containing a plasma kallikrein inhibitor. Plasma kallikrein inhibitors include avoralstat. The compositions and methods include delivery of a plasma kallikrein inhibitor to the suprachoroidal space (SCS) of the eye.
-
公开(公告)号：US10512649B2
公开(公告)日：2019-12-24
申请号：US16082437
申请日：2017-03-06
IPC分类号： A61K31/519 , C07D487/04 , A61P31/14 , A61K9/00
摘要： Disclosed are 9-deazaaadenine derivatives of the general formula (I) and pharmaceutically acceptable salts thereof, wherein A is OH or NH2, and B is H or NH2. Methods for treating, preventing and/or suppressing a Zika virus infection with the compounds disclosed are also provided. Pharmaceutical compositions comprising the disclosed compounds are also provided. Such pharmaceutical compositions may optionally contain one or more additional active agents.
-
公开(公告)号：US10420769B2
公开(公告)日：2019-09-24
申请号：US16013059
申请日：2018-06-20
IPC分类号： A61K31/519 , A61K31/196 , A61K31/215 , A61K31/351 , A61K31/7064 , A61K45/06 , C07H7/06 , C07D487/04 , A61K9/00 , A61P31/14 , A61P31/16
摘要： The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
-
公开(公告)号：US10329260B2
公开(公告)日：2019-06-25
申请号：US15977129
申请日：2018-05-11
发明人： Pravin L. Kotian , Yarlagadda S. Babu , Minwan Wu , Venkat R. Chintareddy , V. Satish Kumar , Weihe Zhang
IPC分类号： C07D231/14 , C07D417/12 , C07D413/12 , C07D413/04 , C07D405/12 , C07D403/12 , C07D401/12 , C07D401/04 , C07D401/14 , C07D403/04
摘要： Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
-
公开(公告)号：US09770427B2
公开(公告)日：2017-09-26
申请号：US14313738
申请日：2014-06-24
IPC分类号： A61K31/215 , A61K31/196 , A61P31/12 , A61P31/16 , A61K31/195 , A61K9/00 , A61K45/06
CPC分类号： A61K31/215 , A61K9/0019 , A61K9/006 , A61K31/195 , A61K31/196 , A61K45/06
摘要： The invention provides unit dosage forms, kits, and methods and useful for treating viral infections.
-
-
-
-
-
-
-
-
-
搜索结果
126 条记录 (耗时 0.044 秒)
